Coherus Oncology (CHRS) Operating Margin Growth (5y) (2019 - 2026)

Coherus Oncology (CHRS) Operating Margin Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Coherus Oncology 195.05 Mn 28.00 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9,212.00
Dec 31, 2025 -37,477.00
Sep 30, 2025 -41,283.00
Jun 30, 2025 -49,173.00
Mar 31, 2025 -63,308.00
Dec 31, 2024 -62,324.00
Sep 30, 2024 -82,064.00
Jun 30, 2024 -41,782.00
Mar 31, 2024 -289,230.00
Jun 30, 2022 397,240.00
Mar 31, 2022 4.48 Mn
Dec 31, 2021 864,988.00
Sep 30, 2021 -9,171.00
Jun 30, 2021 41,838.00
Mar 31, 2021 31,913.00
Dec 31, 2020 52,681.00
Sep 30, 2020 102,337.00
Jun 30, 2020 90,591.00
Mar 31, 2020 66,767.00
Dec 31, 2019 44,541.00